Volume 26, Number 6—June 2020
Research
Invasive Group B Streptococcus Infections in Adults, England, 2015–2016
Simon M. Collin
, Nandini Shetty, and Theresa Lamagni
, Nandini Shetty, and Theresa Lamagni
Table 3
Underlying conditions among adult patients with invasive GBS (iGBS) infection unrelated to pregnancy in England, 2015–2016*
| Conditions |
Age, y |
Total |
|||||||
| 15–19 |
20–29 |
30–39 |
40–49 |
50–59 |
60–69 |
70–79 |
>80 |
||
| No. iGBS episodes | 12 | 49 | 98 | 204 | 339 | 474 | 545 | 785 | 2,506 |
| Diabetes | 1 (8.3) | 5 (10.2) | 17 (17.4) | 62 (30.4) | 162 (47.8) | 212 (44.7) | 267 (49.0) | 274 (34.9) | 1,000 (39.7) |
| Peripheral vascular disease | 1 (8.3) | 5 (10.2) | 31 (31.6) | 46 (22.6) | 113 (33.3) | 154 (32.5) | 203 (37.3) | 289 (36.8) | 842 (33.6) |
| Cancer | 2 (16.7) | 2 (4.1) | 1 (1.0) | 28 (13.7) | 57 (16.8) | 77 (16.2) | 107 (19.6) | 163 (20.8) | 437 (17.4) |
| Cardiovascular disease | 3 (25.0) | 12 (24.5) | 32 (32.7) | 58 (28.4) | 125 (36.9) | 249 (52.5) | 355 (65.1) | 606 (77.2) | 1,440 (57.5) |
| Lung disease | 5 (41.7) | 20 (40.8) | 39 (39.8) | 72 (35.3) | 148 (43.7) | 193 (40.7) | 242 (44.4) | 357 (45.5) | 1,076 (42.9) |
| Kidney disease | 2 (16.7) | 9 (18.4) | 19 (19.4) | 69 (33.8) | 117 (34.5) | 197 (41.6) | 268 (49.2) | 434 (55.3) | 1,115 (44.5) |
| Neurologic disorders | 2 (16.7) | 11 (22.5) | 21 (21.4) | 53 (26.0) | 111 (32.7) | 124 (26.2) | 167 (30.6) | 311 (39.6) | 800 (31.9) |
| Arthritis | 0 | 5 (10.2) | 12 (12.2) | 42 (20.6) | 74 (21.8) | 125 (26.4) | 189 (34.7) | 294 (37.5) | 741 (29.6) |
| None of these | 3 (25.0) | 12 (24.5) | 23 (23.5) | 28 (13.7) | 27 (8.0) | 39 (8.2) | 17 (3.1) | 15 (1.9) | 164 (6.5) |
*Values are no. (%) patients. Predefined conditions (Appendix Table 7) identified in current and prior admissions (up to 1 y prediagnosis). iGBS, invasive group B Streptococcus.
Page created: May 18, 2020
Page updated: May 18, 2020
Page reviewed: May 18, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.